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Introduction
============

Angiotensin-converting enzyme inhibitors (ACEi) are indicated in the management of hypertension, heart failure, and diabetic nephropathy in both young and elderly patients \[[@REF1]\]. Most patients tolerate ACE inhibitors well, but around 30% can develop adverse reactions like symptomatic hypotension and dry cough, however, more severe adverse reactions, including angioedema and renal failure, can also occur \[[@REF2]-[@REF4]\].

ACEi act by inhibiting the conversion of angiotensin I to angiotensin II which is a vasoconstrictive agent. ACEi also increase the levels of bradykinin which increases peripheral vascular permeability and causes vasodilatation. This has also been proposed as the mechanism behind ACEi-induced cough which is mediated by vasoactive kinins (bradykinin) and substance P \[[@REF5]\]. However, a recent report from the Swedish population has concluded otherwise. In their genome-wide association study on ACEi-induced cough, genetic variation rather than bradykinin pathways was found to be the potential culprit \[[@REF6]\]. ACEi-induced cough is still the greatest challenge in the continued utilization of ACEi for management of hypertension.

The incidence of ACEi-induced cough is 2.5-11% in the West, with a discontinuation rate of 4% \[[@REF7], [@REF8]\]. In Japanese patients with class I and II congestive heart failure taking enalapril, the incidence of a drug-induced cough has been reported to be as high as 28% \[[@REF9]\]. In Pakistani patients, the overall incidence of dry cough was 7%. The incidence of cough was 5.5% with perindopril, 7% with ramipril, and 9% with lisinopril \[[@REF10]\]. Older age, female gender, smoking, East Asian ethnicity, ACEi naivety, and history of cough due to another ACEi have been associated with a higher incidence of ACEi-induced cough \[[@REF11], [@REF12]\]. The clinical pattern and related risk factors predisposing patients to ACEi-induced cough have not been studied in Pakistani hypertensive patients as yet. Hence, this study was conducted.

Materials and methods
=====================

A prospective, observational study was conducted with patients attending the clinic of their physicians a tertiary care hospital in Pakistan. After attaining informed consent, patients were requested to participate through a structured questionnaire from 1st June till 31st December 2017. The study was approved by the institutional review board.

The inclusion criteria comprised of individuals of both genders, of age 18 years or more, with known cases of hypertension, taking ACEi for their blood pressure (BP), and having a chronic cough (\>14 days). Only patients who met all of the inclusion criteria were included. It was ensured that the cough was not related to any respiratory etiology. Patients with current respiratory tract infection (RTI), and/or pneumonia, or those who have had an episode of RTI in the last month were excluded. Known cases of asthma, chronic obstructive pulmonary disease, and/or any other chronic respiratory disease were excluded. Newly diagnosed cases of hypertension were not included.

All participants who fulfilled the inclusion criteria and also provided informed consent were requested to fill in a structured questionnaire. It comprised of their baseline information including age, gender, body weight, height, smoking status, and comorbidity status. ACEi related characteristics included type, time of the day, and duration of ACEi usage and time from the start of ACEi to the occurrence of cough. Duration of cough was also recorded. All concomitant drug intake record was also included.

All data were managed using SPSS for Windows version 20.0 (IBM Corp., Armonk, NY). Mean was calculated for continuous data and frequencies were calculated for categorical data. Chi-square was applied for comparison of categorical variables. P-value ≤0.05 was taken as significant.

Results
=======

A total of 123 participants taking ACEi for at least one month were included in this study. Their mean age was 58 ±13 years and there were more men than women (60% vs. 40%). Their demographics and clinical characters are shown in Table [1](#TAB1){ref-type="table"}.

###### Demographic and clinical characteristics of study participants

ACEi - angiotensin-converting enzyme inhibitors; ARBs - angiotensin receptor blockers; BMI - body mass index; H2RA, H2 - receptor antagonists; OHA - oral hypoglycemic agents; PPIs - proton pump inhibitors; SD - standard deviation

  --------------------------------------- ---------------
  Baseline characteristics                Frequency (%)
  Age, years                              
  Mean ± SD                               58 ±13
  \< 45                                   49 (39.8%)
  ≥ 45                                    74 (60.2%)
  Gender                                  
  Male                                    83 (67.5%)
  Female                                  40 (32.5%)
  BMI, kg/m^2^                            
  Mean ± SD                               30.8 ± 5.8
  \< 30                                   51 (41.5%)
  ≥ 30                                    72 (58.5%)
  Smokers                                 80 (65.0%)
  ACEi therapy                            
  Enalapril                               58 (47.2%)
  Captopril                               28 (22.7%)
  Lisinopril                              23 (18.7%)
  Ramipril                                14 (11.4%)
  Duration of ACEi use in years           
  Mean ± SD                               2.5 ± 1.8
  \< 2                                    81 (65.8%)
  ≥ 2                                     42 (34.1%)
  Concomitant drug usage                  
  None                                    25 (20.3%)
  PPIs / H2RA                             98 (79.7%)
  OHA                                     68 (55.3%)
  Nitrates                                34 (27.6%)
  Statins                                 47 (38.2%)
  ARBs                                    27 (21.6%)
  Diuretics                               75 (60.9%)
  Cardioselective B-blocker agents        71 (57.7%)
  Calcium channel blockers                38 (30.8%)
  Platelet aggregation inhibitors         69 (56.1%)
  Co-morbidity status                     
  Cardiovascular diseases                 105 (85.4%)
  Diabetes mellitus type II               79 (64.2%)
  Musculoskeletal disease / arthritis     44 (35.7%)
  Stroke                                  38 (30.8%)
  Neurological disease                    27 (21.9%)
  Genitourinary / nephrological disease   11 (8.9%)
  --------------------------------------- ---------------

As seen in Table [1](#TAB1){ref-type="table"}, enalapril was the most frequently prescribed ACEi in this study followed by captopril, lisinopril, and ramipril was the least common. The demographic characteristics and ACEi-related characteristics were then classified according to the type of ACEi as shown in Table [2](#TAB2){ref-type="table"}. Neither age nor gender of the participants were related to the type of ACEi causing cough. Patient's BMI was statistically related (p=0.002). Smoking status was associated with the type of ACEi causing cough (p=0.008). Duration of ACEi usage and duration of cough was not related. Time of the day the pill was taken was also not statistically related to the type of ACEi causing cough. Time from the start of ACEi to the occurrence of cough was related to the type of ACEi prescribed (p=0.04). All parameters are shown in Table [2](#TAB2){ref-type="table"}.

###### Relationship of demographic and clinical characteristics of the participants with the type of ACEi causing cough

ACEi - angiotensin-converting enzyme inhibitors; ARBs - angiotensin receptor blockers; HTN - hypertensive; BMI - body mass index

  -------------------------------------------------------- ------------------------- ------------------------- -------------------------- ------------------------ ----------------
  Characteristics                                          Enalapril (n=58; 47.2%)   Captopril (n=28; 22.7%)   Lisinopril (n=23; 18.7%)   Ramipril (n=14; 11.4%)   p-value
  Age, years                                                                                                                                                       
  \< 45                                                    27 (46.6%)                10 (35.7%)                7 (30.4%)                  5 (35.7%)                0.52
  ≥ 45                                                     31 (53.4%)                18 (64.3%)                16 (69.5%)                 9 (64.3%)                
  Gender                                                                                                                                                           
  Male                                                     41 (70.7%)                18 (64.3%)                15 (65.2%)                 9 (64.3%)                0.91
  Female                                                   17 (29.3%)                10 (35.7%)                8 (34.7%)                  5 (35.7%)                
  BMI, kg/m^2^                                                                                                                                                     
  \< 30                                                    14 (24.1%)                17 (60.7%)                13 (56.5%)                 7 (50%)                  0.002
  ≥ 30                                                     44 (75.8%)                11 (39.3%)                10 (43.5%)                 7 (50%)                  
  Smoking status                                                                                                                                                   
  Smokers                                                  34 (58.6%)                23 (82.1%)                18 (78.3%)                 5 (35.7%)                0.008
  Duration of ACEi use, years                                                                                                                                      
  \< 2                                                     36 (62.1%)                20 (71.4%)                15 (65.2%)                 10 (71.4%)               0.81
  ≥ 2                                                      22 (37.9%)                8 (28.5%)                 8 (34.7%)                  4 (28.5%)                
  Duration of cough, months                                                                                                                                        
  \< 2                                                     35 (60.3%)                15 (53.5%)                18 (78.3%)                 8 (57.1%)                0.30
  ≥ 2                                                      23 (39.6%)                13 (46.4%)                5 (21.7%)                  6 (42.9%)                
  Time from start of ACEi to occurrence of cough, months                                                                                                           
  \< 1                                                     13 (22.4%)                7 (25%)                   10 (43.5%)                 8 (57.1%)                0.04
  1-3                                                      20 (34.5%)                10 (35.7%)                9 (39.1%)                  5 (35.7%)                
  \> 3                                                     25 (43.1%)                11 (39.3%)                4 (17.4%)                  1 (7.1%)                 
  Time of the day ACEi is taken                                                                                                                                    
  Morning only                                             21 (36.2%)                12 (42.8%)                8 (34.7%)                  5 (35.7%)                0.97
  Bedtime only                                             20 (34.4%)                10 (35.7%)                7 (30.4%)                  5 (35.7%)                
  Morning and bedtime                                      17 (29.3%)                6 (21.4%)                 8 (34.7%)                  4 (28.5%)                
  Concomitant Anti-HTN therapy                                                                                                                                     
  None                                                     18 (31.0%)                13 (46.4%)                10 (43.5%)                 5 (35.7%)                Not applicable
  ARBs                                                     11 (18.9%)                \-                        2 (8.7%)                   \-                       
  Diuretics                                                9 (15.5%)                 5 (17.8%)                 5 (21.7%)                  4 (28.5%)                
  B-blockers                                               10 (17.2%)                6 (21.4%)                 2 (8.7%)                   2 (14.3%)                
  Calcium channel blockers                                 10 (17.2%)                4 (14.3%)                 4 (17.4%)                  3 (21.4%)                
  -------------------------------------------------------- ------------------------- ------------------------- -------------------------- ------------------------ ----------------

There were 48 (39%) participants who were taking ACEi only and no other concomitant drug. Their ACEi related characteristics are shown in Figure [1](#FIG1){ref-type="fig"}.
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When the patients were asked if their cough is significant enough to stop taking their ACEi, 33 (26.8%) responded that they plan to request their physician to prescribe them an alternate medication.

Discussion
==========

In this study, it was deduced that among the ACEi users presenting with cough, enalapril was the most commonly prescribed ACEi. Higher BMI, smoking, and longer time from the start of ACEi to the occurrence of cough are related to ACEi-induced cough.

When Haldberg et al. studied 121 patients of ACEi-induced cough, they found that enalapril was the culprit in 88% cases. As compared to our results, they did not find a statistical relationship of ACEi-induced cough with longer time to onset of cough and smoking \[[@REF5]\]. In an analysis of three large trials on perindopril-induced cough, the rate of discontinuation was 4%. Significant determinants of cough included female gender, old age (\>65 years), and simultaneous use of lipid-lowering agents \[[@REF8]\]. In a large cohort, there were two and a half times higher risk of ACEi-induced cough in patients with a history of smoking and in East Asians patients. A twelve times higher risk in patients who have experienced cough with any other ACEi. ACEi discontinuation rate due to cough was 19% \[[@REF11]\]. In this study, 27% of participants planned to request discontinuation of therapy to their physician. In a Singaporean report, the rate of therapy discontinuation due to ACEi-induced cough was 30% \[[@REF13]\]. In another cohort of 1,700 patients taking ACEi, 12% developed a cough. The determinants of cough in this cohort were older age, female gender, non-African American ethnicity, ACEi naivety, and previous history of cough due to any other ACEi \[[@REF12]\].

There has only been one report of ACEi-induced cough from Pakistan. They reported an overall 7% incidence of cough with ACEi use which was highest with lisinopril (9%). They did not report any data on enalapril which was the most common triggering agent in our report. The incidence of ramipril-related cough was 6.8% in their report \[[@REF10]\]. In our analysis, 11% of ACEi-induced cough was due to ramipril. In a report from Poland, the incidence of ramipril-related cough was 7%. The factors determining the risk of cough in the Polish report were female gender, smoking, and respiratory illnesses including asthma, chronic obstructive pulmonary disease, and tuberculosis \[[@REF14]\]. In a prospective study from Bahrain, 37% developed a perindopril-induced cough after the mean duration of onset of 12.7 days. After stopping or changing the drug, the mean for cough disappearance was 13.3 days. The ACEi-induced cough was related to female gender and not related to age or BMI \[[@REF15]\]. In our study, BMI was a statistically significant determinant.

To the best of our knowledge, the characteristics of ACEi-induced cough have been studied for the first time in this study in Pakistani population. It was an observational study and controlled trials can be better utilized for more generalized results. The concept of pharmacovigilance (PV) is pretty much non-existent in the current pharmaceutical industry of Pakistan \[[@REF16]\]. In order to comprehend the impact of ACEi-induced cough and other adverse drug reactions on the population, designing and implementing PV programs has become a grave necessity. Reports from country-wide PV records will give a more wholesome perspective of the situation.

Conclusions
===========

Despite their common utilization in hypertension and heart failure, adverse events associated with ACE inhibitors remain a major challenge for the physicians. The ACEi-induced cough may be severe enough to push the patients towards the discontinuation of therapy in some cases. Enalapril was most commonly associated with cases of ACEi-induced dry cough. Patient factors determining higher risk included high BMI, smoking, and longer time to onset of cough from the start of ACEi usage.
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